PO.CH01.01 · 化学
Targeted Protein Degradation and Induced Proximity
-
-
-
-
- 5154 5154 Proteolysis and gene silencing targeting chimera (PROGENTAC) Abhay Prasad, Rong Zheng, Deeksha Satyabola, Yang Xu, Yichen Yan, Hao Yan
-
-
- 5158 5158 Preclinical characterization of HY809382, a highly potent and orally bioavailable PRC2 PROTAC, for the treatment of lymphoma and solid tumors Huangtao Jin, Juan Du, Ruwei Wang, Zengrong Li, Ting Zhang, Xing Yu, Ming Weng, Xiaoxiao Wang, Xiaohong Hou, Feifei Yang, Xin Li, Weixing Zhu, Liming Zhang, Lei Chen, Sai Yang, Feng Xu, Qian Ma, Ruowen Zhang, Xiaotian Huang
-
- 5161 5161 HJ-004, a potent and selective pan-EGFR mutation targeted protein degrader (TPD) that effectively overcomes osimertinib resistance in EGFR-mutant NSCLC Li Zeng, Yao Liu, Ya Geng, Yue Zhu
-
-
- 5166 5166 NRX-4972, a selective, oral, Aurora kinase A degrader, demonstrates increased efficacy in an SCLC tumor model, and greater in vitro synergy than an AURKA inhibitor Hua Tian, Ryan B. Rountree, Jeffrey T. Mihalic, Eric R. Wegrzyniak, Ge Wei, Karthik Arumugam, Paul L. Auger, Graham J. Carlson, Robert T. Cass, Tarra Knotts, Filippo Marchioni, Daniel Medina-Cleghorn, Michael G. Mormino, Madeleine P. Nemchek, Rusha M. Sardhara, Sangita Sridharan, Austin Tenn-McClellan, Simon Vezina-Dawod, Gwenn M. Hansen
-
-
-
-
- 5171 5171 The EGFR-PROTAC molecule TY-2719 attenuates acquired resistance to 3rd-generation EGFR TKIs and augments the efficacy of KRAS mutant inhibitors in solid tumors Apeng Liang*, #, Shengli Dong*, #, Shaoqing Chen*, Hongqiang Li, Zhiyong He, Zhengfei Guo, Meihua Li, Shunxun Han, Guangbin Liu, Xi Wang, Yanyan Liu, Ling Fang, Yi Long, Xiang Zhang, Wei Wu, Chengshan Niu, Jun Li, Yusheng Wu
-
- 5173 5173 Identification of a small molecule degrader targeting SALL4 oncogene Kim Anh L. Vu, Shiva Moein, Kalpana Kumari, Bee Hui Liu, Miao Liu, Chong Gao, Li Feng, Mahmoud Bassal, Douglas Auld, Dominik Casalena, Qiling Zhou, Daniel G. Tenen, Li Chai
-
- 5175 5175 Discovery and characterization of once in a month intravenous and orally bioavailable SMARCA2 degraders for treating SMARCA4 mutant cancers Bilash Kuila, Kiran B. Aithal, Sandeep Vitthal Dukare, Charamanna KB, Khaji Abdul Rawoof, Prasath Kothandaraman, Amit A. Dhudashiya, Nandish C, Payel Das, Anuradha Gadeval, Madhu K L, Bhagwan Mahadeo Dhaytadak, Gopinath CH, T Jagadeesh Kumar, Suraj Tgore, Mohamad Fairus Bin Abdul Kadir, Leena Khare, Ranadeep Bokalial, Samiulla DS, Subhendu Mukherjee, Saravanan Thiyagarajan, Kavitha Nellore, Rajesh Eswarappa, Girish Daginakatte, Chandrasekhar Abbineni, Sanjeev Giri, Murali Ramachandra, Susanta Samajdar
-
-
-
-
-
